These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11303953)

  • 1. Influence of passive permeability on apparent P-glycoprotein kinetics.
    Lentz KA; Polli JW; Wring SA; Humphreys JE; Polli JE
    Pharm Res; 2000 Dec; 17(12):1456-60. PubMed ID: 11303953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
    Taub ME; Podila L; Ely D; Almeida I
    Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
    Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
    PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
    Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
    J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
    Tang F; Borchardt RT
    Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
    Tang F; Borchardt RT
    Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
    Horie K; Tang F; Borchardt RT
    Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
    Troutman MD; Thakker DR
    Pharm Res; 2003 Aug; 20(8):1210-24. PubMed ID: 12948019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.
    Makhey VD; Guo A; Norris DA; Hu P; Yan J; Sinko PJ
    Pharm Res; 1998 Aug; 15(8):1160-7. PubMed ID: 9706044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
    Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
    J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
    Profit L; Eagling VA; Back DJ
    AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.
    Shirasaka Y; Sakane T; Yamashita S
    J Pharm Sci; 2008 Jan; 97(1):553-65. PubMed ID: 17828734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
    Dahan A; Amidon GL
    Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
    Karyekar CS; Eddington ND; Garimella TS; Gubbins PO; Dowling TC
    Pharmacotherapy; 2003 Apr; 23(4):436-42. PubMed ID: 12680473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
    Troutman MD; Thakker DR
    Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.
    Tolle-Sander S; Rautio J; Wring S; Polli JW; Polli JE
    Pharm Res; 2003 May; 20(5):757-64. PubMed ID: 12751631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative and Mechanistic Assessment of Model Lipophilic Drugs in Micellar Solutions in the Transport Kinetics Across MDR1-MDCK Cell Monolayers.
    Ho NFH; Nielsen J; Peterson M; Burton PS
    J Pharm Sci; 2016 Feb; 105(2):904-914. PubMed ID: 26869435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone.
    Wu SJ; Robinson JR
    Pharm Res; 1999 Aug; 16(8):1266-72. PubMed ID: 10468030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport characteristics of fexofenadine in the Caco-2 cell model.
    Petri N; Tannergren C; Rungstad D; Lennernäs H
    Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells.
    Meng Z; Ellens H; Bentz J
    Drug Metab Dispos; 2017 Feb; 45(2):190-197. PubMed ID: 27856526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.